Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
An article from
News roundup
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
Published May 20, 2026
Getty Images
Immunovant e Roivant Sciences disparam com novo tratamento para artrite reumatoide
A new ranking of pharma companies by R&D performance
Wave aims for monthly dosing with RNA editing treatment for AATD
Supreme Court declines to hear IRA challenges from Novo, AZ and more
Drugmakers guard IP more tightly amid China competition
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug - ImmunityBio (NASDAQ
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
Takeda slapped with $885M verdict in pay-for-delay antitrust case
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
